Published in Gut on September 01, 2004
14-day Quadruple Hybrid vs. Concomitant Therapies for Helicobacter Pylori Eradication | NCT01464060
Comparing the Efficacy of Reverse Hybrid Therapy and Bismuth Quadruple Therapy | NCT02547038
Personalized Treatment for Refractory H Pylori Infection | NCT02547025
Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut (2006) 9.03
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet (2011) 5.21
Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev (2007) 3.43
The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut (2007) 3.15
Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER Study. Gut (2006) 2.56
Therapy of Helicobacter pylori: present medley and future prospective. Biomed Res Int (2014) 2.56
Optimal therapy for Helicobacter pylori infections. Nat Rev Gastroenterol Hepatol (2011) 1.98
Epidemiology and pattern of antibiotic resistance in Helicobacter pylori: scenario from Saudi Arabia. Saudi J Gastroenterol (2014) 1.97
Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter (2011) 1.73
A new look at anti-Helicobacter pylori therapy. World J Gastroenterol (2011) 1.59
In vivo treatment of Helicobacter pylori infection with liposomal linolenic acid reduces colonization and ameliorates inflammation. Proc Natl Acad Sci U S A (2014) 1.48
Evaluation of a new test, genotype HelicoDR, for molecular detection of antibiotic resistance in Helicobacter pylori. J Clin Microbiol (2009) 1.41
Importance of antimicrobial susceptibility testing for the management of eradication in Helicobacter pylori infection. World J Gastroenterol (2017) 1.38
How antibiotic resistances could change Helicobacter pylori treatment: A matter of geography? World J Gastroenterol (2013) 1.34
Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther (2015) 1.22
Helicobacter pylori and antibiotic resistance. Gut (2007) 1.17
Quadruplex real-time PCR assay using allele-specific scorpion primers for detection of mutations conferring clarithromycin resistance to Helicobacter pylori. J Clin Microbiol (2008) 1.14
Recent Insights into Antibiotic Resistance in Helicobacter pylori Eradication. Gastroenterol Res Pract (2012) 1.12
High prevalence of clarithromycin-resistant Helicobacter pylori strains and risk factors associated with resistance in Madrid, Spain. J Clin Microbiol (2010) 1.11
Mechanisms of Helicobacter pylori antibiotic resistance: An updated appraisal. World J Gastrointest Pathophysiol (2011) 1.10
Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis. Wien Klin Wochenschr (2010) 1.10
Rescue Therapy for Helicobacter pylori Infection 2012. Gastroenterol Res Pract (2012) 1.10
Genotypic resistance in Helicobacter pylori strains correlates with susceptibility test and treatment outcomes after levofloxacin- and clarithromycin-based therapies. Antimicrob Agents Chemother (2010) 1.10
Antimicrobial susceptibility and mutations involved in clarithromycin resistance in Helicobacter pylori isolates from patients in the western central region of Colombia. Antimicrob Agents Chemother (2009) 1.08
The stringent response is required for Helicobacter pylori survival of stationary phase, exposure to acid, and aerobic shock. J Bacteriol (2006) 1.07
Helicobacter pylori antibiotic resistance in Iran. World J Gastroenterol (2005) 1.07
Characteristics and Risk Factors of Helicobacter pylori Associated Gastritis: A Prospective Cross-Sectional Study in Northeast Thailand. Gastroenterol Res Pract (2016) 1.07
Exploring the cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer in China in anticipation of clinical trial results. Int J Cancer (2009) 1.06
High frequency of A2143G mutation in clarithromycin-resistant Helicobacter pylori isolates recovered from dyspeptic patients in Iran. Saudi J Gastroenterol (2011) 1.05
Bactericidal and anti-adhesive properties of culinary and medicinal plants against Helicobacter pylori. World J Gastroenterol (2005) 1.05
Frequency of antibiotic resistance in Helicobacter pylori strains isolated from the northern population of Iran. J Microbiol (2011) 1.04
Efficacy of 7-Day and 14-Day Bismuth-Containing Quadruple Therapy and 7-Day and 14-Day Moxifloxacin-Based Triple Therapy as Second-Line Eradication for Helicobacter pylori Infection. Gut Liver (2015) 1.04
The prevention of infection-associated cancers. Carcinogenesis (2011) 1.03
Eradication of Helicobacter pylori infection: which regimen first? World J Gastroenterol (2014) 1.03
Third-line rescue therapy for Helicobacter pylori infection. World J Gastroenterol (2006) 1.02
Immune evasion by Helicobacter pylori is mediated by induction of macrophage arginase II. J Immunol (2011) 1.02
Antimicrobial susceptibility of Helicobacter pylori strains isolated from patients in Shiraz, Southern Iran. World J Gastroenterol (2010) 1.01
Evaluation of Helicobacter pylori eradication by triple therapy plus Lactobacillus acidophilus compared to triple therapy alone. Eur J Clin Microbiol Infect Dis (2011) 1.01
Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Clin Exp Gastroenterol (2012) 1.00
"Rescue" regimens after Helicobacter pylori treatment failure. World J Gastroenterol (2008) 0.99
Treatment of Helicobacter pylori infection: meeting the challenge of antimicrobial resistance. World J Gastroenterol (2014) 0.99
Relationship between H.Pylori infection and clinicopathological features and prognosis of gastric cancer. BMC Cancer (2010) 0.98
Are probiotics useful in Helicobacter pylori eradication? World J Gastroenterol (2015) 0.97
Antibacterial activities of liposomal linolenic acids against antibiotic-resistant Helicobacter pylori. Mol Pharm (2012) 0.97
Helicobacter pylori therapy: Present and future. World J Gastrointest Pharmacol Ther (2012) 0.97
Antibiotic resistance of Helicobacter pylori from patients in Ile-Ife, South-west, Nigeria. Afr Health Sci (2007) 0.96
Treatment of Helicobacter pylori infection: Past, present and future. World J Gastrointest Pathophysiol (2014) 0.96
Meta-analysis of the efficacy of probiotics in Helicobacter pylori eradication therapy. World J Gastroenterol (2014) 0.96
Clinical role and importance of fluorescence in situ hybridization method in diagnosis of H pylori infection and determination of clarithromycin resistance in H pylori eradication therapy. World J Gastroenterol (2007) 0.94
Distribution of spontaneous gyrA mutations in 97 fluoroquinolone-resistant Helicobacter pylori isolates collected in France. Antimicrob Agents Chemother (2011) 0.94
Antibiotic susceptibility profile of Helicobacter pylori isolated from the dyspepsia patients in Tehran, Iran. Saudi J Gastroenterol (2011) 0.93
Antimicrobial susceptibility and resistance patterns among Helicobacter pylori strains from The Gambia, West Africa. Antimicrob Agents Chemother (2012) 0.93
Characterization of clarithromycin resistance in Malaysian isolates of Helicobacter pylori. World J Gastroenterol (2009) 0.93
Virulence factors and antibiotic resistance of Helicobacter pylori isolated from raw milk and unpasteurized dairy products in Iran. J Venom Anim Toxins Incl Trop Dis (2014) 0.92
Current recommendations for Helicobacter pylori therapies in a world of evolving resistance. Gut Microbes (2013) 0.92
Randomized controlled trial comparing 7-day triple, 10-day sequential, and 7-day concomitant therapies for Helicobacter pylori infection. Antimicrob Agents Chemother (2014) 0.91
Improving compliance with helicobacter pylori eradication therapy: when and how? Therap Adv Gastroenterol (2009) 0.91
Sequential Therapy for Helicobacter Pylori Eradication: The Time is Now! Therap Adv Gastroenterol (2009) 0.90
Primary resistance to clarithromycin, metronidazole and amoxicillin of Helicobacter pylori isolated from Tunisian patients with peptic ulcers and gastritis: a prospective multicentre study. Ann Clin Microbiol Antimicrob (2010) 0.90
Primary clarithromycin resistance to Helicobacter pylori: Is this the main reason for triple therapy failure? World J Gastrointest Pathophysiol (2013) 0.90
The Optimal First-Line Therapy of Helicobacter pylori Infection in Year 2012. Gastroenterol Res Pract (2012) 0.90
Functional identification of toxin-antitoxin molecules from Helicobacter pylori 26695 and structural elucidation of the molecular interactions. J Biol Chem (2010) 0.89
Antimicrobial resistance of H. pylori to the outcome of 10-days vs. 7-days Moxifloxacin based therapy for the eradication: a randomized controlled trial. Ann Clin Microbiol Antimicrob (2010) 0.89
Prevalence of A2143G mutation of H. pylori-23S rRNA in Chinese subjects with and without clarithromycin use history. BMC Microbiol (2008) 0.89
Second-line rescue therapy of helicobacter pylori infection. Therap Adv Gastroenterol (2009) 0.89
Treatment of Helicobacter pylori infection: current status and future concepts. World J Gastroenterol (2014) 0.89
Helicobacter pylori in vegetables and salads: genotyping and antimicrobial resistance properties. Biomed Res Int (2014) 0.89
Detection of A2142C, A2142G, and A2143G Mutations in 23s rRNA Gene Conferring Resistance to Clarithromycin among Helicobacter pylori Isolates in Kerman, Iran. Iran J Med Sci (2011) 0.88
Age-dependent eradication of Helicobacter pylori in Japanese patients. World J Gastroenterol (2010) 0.88
Trends in the eradication rates of Helicobacter pylori infection for eleven years. World J Gastroenterol (2012) 0.88
Alaska sentinel surveillance study of Helicobacter pylori isolates from Alaska Native persons from 2000 to 2008. J Clin Microbiol (2011) 0.88
The incidence of primary antibiotic resistance of Helicobacter pylori in Vietnam. J Clin Gastroenterol (2013) 0.87
In vitro characterization of the anti-bacterial activity of SQ109 against Helicobacter pylori. PLoS One (2013) 0.87
Helicobacter pylori Eradication Therapies in the Era of Increasing Antibiotic Resistance: A Paradigm Shift to Improved Efficacy. Gastroenterol Res Pract (2012) 0.87
Comparison of azithromycin and metronidazole in a quadruple-therapy regimen for Helicobacter pylori eradication in dyspepsia. Saudi J Gastroenterol (2009) 0.87
Update on Therapeutic Options for Helicobacter pylori-related Diseases. Curr Infect Dis Rep (2005) 0.86
Efficacy of levofloxacin and rifaximin based quadruple therapy in Helicobacter pylori associated gastroduodenal disease: a double-blind, randomized controlled trial. J Korean Med Sci (2011) 0.86
Helicobacter pylori in Iran: A systematic review on the antibiotic resistance. Iran J Basic Med Sci (2015) 0.86
Discovery of novel mutations for clarithromycin resistance in Helicobacter pylori by using next-generation sequencing. J Antimicrob Chemother (2014) 0.86
Validation of a fluorescence in situ hybridization method using peptide nucleic acid probes for detection of Helicobacter pylori clarithromycin resistance in gastric biopsy specimens. J Clin Microbiol (2013) 0.86
Second-line treatment for Helicobacter pylori infection based on moxifloxacin triple therapy: a randomized controlled trial. Wien Klin Wochenschr (2009) 0.86
Quadruple therapy with moxifloxacin and bismuth for first-line treatment of Helicobacter pylori. World J Gastroenterol (2012) 0.85
Helicobacter pylori infection in hemodialysis patients: susceptibility to amoxicillin and clarithromycin. World J Gastroenterol (2005) 0.85
Advances in gastric cancer prevention. World J Clin Oncol (2012) 0.85
Rapid detection of clarithromycin resistant Helicobacter pylori strains in Spanish patients by polymerase chain reaction-restriction fragment length polymorphism. Rev Esp Quimioter (2011) 0.85
In vitro activity of nemonoxacin, tigecycline, and other antimicrobial agents against Helicobacter pylori isolates in Taiwan, 1998-2007. Eur J Clin Microbiol Infect Dis (2010) 0.84
Primary Antibiotic Resistance to Helicobacter pylori Strains Isolated From Children in Northern Iran: A Single Center Study. Iran J Pediatr (2015) 0.84
Standard triple therapy for Helicobacter pylori infection in China: a meta-analysis. World J Gastroenterol (2014) 0.84
Phenotypic and genetic characterization of antimicrobial profiles of Helicobacter pylori strains in Cuba. J Health Popul Nutr (2010) 0.84
Detection of clarithromycin resistance in Helicobacter pylori following noncryogenic storage of rapid urease tests for 30 days. J Dig Dis (2012) 0.84
Antibiotics resistance rate of Helicobacter pylori in Bhutan. World J Gastroenterol (2013) 0.84
Role of Helicobacter pylori infection in gastric carcinogenesis: Current knowledge and future directions. World J Gastroenterol (2015) 0.83
Sitafloxacin activity against Helicobacter pylori isolates, including those with gyrA mutations. Antimicrob Agents Chemother (2009) 0.83
Contribution of specific amino acid changes in penicillin binding protein 1 to amoxicillin resistance in clinical Helicobacter pylori isolates. Antimicrob Agents Chemother (2010) 0.83
Detection of Helicobacter pylori in Various Types of Vegetables and Salads. Jundishapur J Microbiol (2014) 0.82
Vaccine against Helicobacter pylori: Inevitable approach. World J Gastroenterol (2016) 0.82
Variability in Prevalence of Helicobacter pylori Strains Resistant to Clarithromycin and Levofloxacin in Southern Poland. Gastroenterol Res Pract (2012) 0.82
Update on triple therapy for eradication of Helicobacter pylori: current status of the art. Clin Exp Gastroenterol (2012) 0.82
Nitazoxanide Use as Part of an Empiric Multi-Drug Regimen in Treating Children with Suspected Helicobacter pylori Infection. Case Rep Gastroenterol (2014) 0.82
Hybrid therapy for Helicobacter pylori infection: A systemic review and meta-analysis. World J Gastroenterol (2015) 0.81
The LightCycler: a microvolume multisample fluorimeter with rapid temperature control. Biotechniques (1997) 11.94
Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther (2002) 6.17
Variation in antibiotic use in the European Union. Lancet (2001) 6.02
Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori. Antimicrob Agents Chemother (1996) 6.01
The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections. Ann Intern Med (2003) 4.65
Macrolide resistance in Helicobacter pylori: rapid detection of point mutations and assays of macrolide binding to ribosomes. Antimicrob Agents Chemother (1997) 3.27
Macrolide resistance in Helicobacter pylori: mechanism and stability in strains from clarithromycin-treated patients. Antimicrob Agents Chemother (1997) 2.73
The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology (1999) 2.64
A PCR-oligonucleotide ligation assay to determine the prevalence of 23S rRNA gene mutations in clarithromycin-resistant Helicobacter pylori. Antimicrob Agents Chemother (1997) 2.63
Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol (1998) 2.38
Mutations in the beginning of the rpoB gene can induce resistance to rifamycins in both Helicobacter pylori and Mycobacterium tuberculosis. Antimicrob Agents Chemother (2000) 2.25
Stable amoxicillin resistance in Helicobacter pylori. Lancet (1998) 2.20
A systematic review of Helicobacter pylori eradication therapy--the impact of antimicrobial resistance on eradication rates. Aliment Pharmacol Ther (1999) 2.14
European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis (2001) 2.10
Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: the MACH 2 study. Antimicrob Agents Chemother (1999) 2.07
Detection of point mutations associated with resistance of Helicobacter pylori to clarithromycin by hybridization in liquid phase. J Clin Microbiol (1998) 2.02
A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: The QUADRATE Study. Gastroenterology (2002) 1.94
Nucleotide sequence of the gyrA gene and characterization of ciprofloxacin-resistant mutants of Helicobacter pylori. Antimicrob Agents Chemother (1995) 1.94
Epidemiology and mechanism of antibiotic resistance in Helicobacter pylori. Gastroenterology (1998) 1.86
Helicobacter pylori antimicrobial resistance in the United Kingdom: the effect of age, sex and socio-economic status. Aliment Pharmacol Ther (2001) 1.81
Rifampin and rifabutin resistance mechanism in Helicobacter pylori. Antimicrob Agents Chemother (1999) 1.80
Risk factors for failure of Helicobacter pylori therapy--results of an individual data analysis of 2751 patients. Aliment Pharmacol Ther (2003) 1.76
Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxycillin, tetracycline and trovafloxacin in The Netherlands. J Antimicrob Chemother (1999) 1.73
Mutations in the 16S rRNA genes of Helicobacter pylori mediate resistance to tetracycline. J Bacteriol (2002) 1.70
Analysis of metronidazole, clarithromycin and tetracycline resistance of Helicobacter pylori isolates from Korea. J Antimicrob Chemother (2001) 1.68
Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States. Arch Intern Med (2001) 1.66
Results of a multicentre European survey in 1991 of metronidazole resistance in Helicobacter pylori. European Study Group on Antibiotic Susceptibility of Helicobacter pylori. Eur J Clin Microbiol Infect Dis (1992) 1.65
Novel method for rapid determination of clarithromycin sensitivity in Helicobacter pylori. J Clin Microbiol (1999) 1.62
Rapid and specific detection of Helicobacter pylori macrolide resistance in gastric tissue by fluorescent in situ hybridisation. Gut (2000) 1.62
Real-time PCR assay for rapid and accurate detection of point mutations conferring resistance to clarithromycin in Helicobacter pylori. J Clin Microbiol (2003) 1.60
Helicobacter pylori in children and adolescents: increase of primary clarithromycin resistance, 1997-2000. J Pediatr Gastroenterol Nutr (2003) 1.59
Changing pattern of antimicrobial resistance of Helicobacter pylori in Korean patients with peptic ulcer diseases. J Gastroenterol (2003) 1.57
Clarithromycin-resistance and point mutations in the 23S rRNA gene in Helicobacter pylori isolates from Japan. J Gastroenterol Hepatol (2000) 1.57
Explaining the bias in the 23S rRNA gene mutations associated with clarithromycin resistance in clinical isolates of Helicobacter pylori. Antimicrob Agents Chemother (1998) 1.56
Single and double mutations in gyrA but not in gyrB are associated with low- and high-level fluoroquinolone resistance in Helicobacter pylori. Antimicrob Agents Chemother (2003) 1.55
Features and trends in Helicobacter pylori antibiotic resistance in Lisbon area, Portugal (1990-1999). J Antimicrob Chemother (2000) 1.54
Review article: the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther (2003) 1.49
Relationship between eradication therapy and clarithromycin-resistant Helicobacter pylori in Japan. J Gastroenterol (2000) 1.48
Secondary resistance among 554 isolates of Helicobacter pylori after failure of therapy. Eur J Clin Microbiol Infect Dis (2000) 1.45
Resistance of helicobacter pylori to metronidazole, tetracycline and amoxycillin. J Antimicrob Chemother (2000) 1.44
Increasing multidrug resistance in Helicobacter pylori strains isolated from children and adults in Mexico. J Clin Microbiol (2001) 1.44
Canadian Helicobacter pylori Consensus Conference update: infections in adults. Canadian Helicobacter Study Group. Can J Gastroenterol (1999) 1.43
Clarithromycin resistance in Helicobacter pylori: prevalence in untreated dyspeptic patients and stability in vitro. J Antimicrob Chemother (1996) 1.42
PCR-based diagnosis of Helicobacter pylori infection and real-time determination of clarithromycin resistance directly from human gastric biopsy samples. J Clin Microbiol (2001) 1.42
New site of modification of 23S rRNA associated with clarithromycin resistance of Helicobacter pylori clinical isolates. Antimicrob Agents Chemother (2002) 1.38
Role of antimicrobial susceptibility testing on efficacy of triple therapy in Helicobacter pylori eradication. Aliment Pharmacol Ther (2000) 1.38
Comparison of fluorescent in situ hybridization and conventional culturing for detection of Helicobacter pylori in gastric biopsy specimens. J Clin Microbiol (2001) 1.37
Clinical relevance of resistant strains of Helicobacter pylori: a review of current data. Gut (1998) 1.32
Rapid detection, by PCR and reverse hybridization, of mutations in the Helicobacter pylori 23S rRNA gene, associated with macrolide resistance. Antimicrob Agents Chemother (1999) 1.30
Analysis of antimicrobial susceptibility and virulence factors in Helicobacter pylori clinical isolates. BMC Gastroenterol (2003) 1.29
Emergence of tetracycline resistance in Helicobacter pylori: multiple mutational changes in 16S ribosomal DNA and other genetic loci. Antimicrob Agents Chemother (2002) 1.27
High levels of resistance to metronidazole and clarithromycin in Helicobacter pylori strains in children. J Clin Microbiol (2001) 1.25
Detection of clarithromycin-resistant helicobacter pylori strains by a preferential homoduplex formation assay. J Clin Microbiol (2000) 1.24
Fast and accurate quantitative detection of Helicobacter pylori and identification of clarithromycin resistance mutations in H. pylori isolates from gastric biopsy specimens by real-time PCR. J Clin Microbiol (2003) 1.23
Rapid detection of mutations in the 23S rRNA gene of Helicobacter pylori that confers resistance to clarithromycin treatment to the bacterium. J Clin Microbiol (2001) 1.23
16S rRNA mutation-mediated tetracycline resistance in Helicobacter pylori. Antimicrob Agents Chemother (2002) 1.21
PCR-restriction fragment length polymorphism can also detect point mutation A2142C in the 23S rRNA gene, associated with Helicobacter pylori resistance to clarithromycin. Antimicrob Agents Chemother (2002) 1.19
Regional differences in metronidazole resistance and increasing clarithromycin resistance among Helicobacter pylori isolates from Japan. Antimicrob Agents Chemother (2000) 1.18
Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials. Am J Gastroenterol (2000) 1.18
Latin-American Consensus Conference on Helicobacter pylori infection. Latin-American National Gastroenterological Societies affiliated with the Inter-American Association of Gastroenterology (AIGE). Am J Gastroenterol (2000) 1.17
Antibiotic susceptibility of Helicobacter pylori in Germany: stable primary resistance from 1995 to 2000. J Med Microbiol (2002) 1.17
Clarithromycin resistance among Helicobacter pylori strains isolated from children: prevalence and study of mechanism of resistance by PCR-restriction fragment length polymorphism analysis. J Clin Microbiol (2003) 1.16
Is the molecular basis of metronidazole resistance in microaerophilic organisms understood? Trends Microbiol (2002) 1.15
The report of the Digestive Health InitiativeSM International Update Conference on Helicobacter pylori. Gastroenterology (1997) 1.14
Effects of 16S rRNA gene mutations on tetracycline resistance in Helicobacter pylori. Antimicrob Agents Chemother (2003) 1.13
Characterization of an In vitro-selected amoxicillin-resistant strain of Helicobacter pylori. Antimicrob Agents Chemother (2000) 1.12
Primary and secondary antibiotic resistance of Helicobacter pylori strains isolated in central Italy during the years 1998-2002. Dig Liver Dis (2003) 1.12
Characterization of the genes rdxA and frxA involved in metronidazole resistance in Helicobacter pylori. Res Microbiol (2003) 1.11
Efficacy and safety of single-triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole, for the eradication of Helicobacter pylori: an international multicentre study. Aliment Pharmacol Ther (2003) 1.11
High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized study. Aliment Pharmacol Ther (2002) 1.10
The relationship between consumption of antimicrobial agents and the prevalence of primary Helicobacter pylori resistance. Helicobacter (2002) 1.10
Different penicillin-binding protein profiles in amoxicillin-resistant Helicobacter pylori. Helicobacter (1999) 1.10
Comparison of the E test and agar dilution method for antimicrobial suceptibility testing of Helicobacter pylori. Eur J Clin Microbiol Infect Dis (2002) 1.10
The status of antimicrobial resistance of Helicobacter pylori in eastern Europe. Clin Microbiol Infect (2002) 1.09
PCR using 3'-mismatched primers to detect A2142C mutation in 23S rRNA conferring resistance to clarithromycin in Helicobacter pylori clinical isolates. J Clin Microbiol (2000) 1.09
High-level beta-lactam resistance associated with acquired multidrug resistance in Helicobacter pylori. Antimicrob Agents Chemother (2003) 1.09
Efficacy of two different dosage regimens of omeprazole, amoxycillin and metronidazole for the cure of Helicobacter pylori infection. Aliment Pharmacol Ther (1999) 1.08
Validation of diffusion methods for macrolide susceptibility testing of Helicobacter pylori. Microb Drug Resist (2002) 1.08
A 9 year study of clarithromycin and metronidazole resistance in Helicobacter pylori from Spanish children. J Antimicrob Chemother (2001) 1.07
Fluorescence in situ hybridization vs. epsilometer test for detection of clarithromycin-susceptible and clarithromycin-resistant Helicobacter pylori strains in gastric biopsies from children. Aliment Pharmacol Ther (2002) 1.07
Alterations in penicillin-binding protein 1A confer resistance to beta-lactam antibiotics in Helicobacter pylori. Antimicrob Agents Chemother (2002) 1.07
Twelve year observation of primary and secondary antibiotic-resistant Helicobacter pylori strains in children. Pediatr Infect Dis J (2001) 1.06
Helicobacter pylori primary resistance to metronidazole and clarithromycin in Brazil. Antimicrob Agents Chemother (2002) 1.04
Mutations in the 23S rRNA gene of Helicobacter pylori associated with clarithromycin resistance. J Korean Med Sci (2002) 1.03
Prevalence of Helicobacter pylori resistance to antibiotics in Northeast Italy: a multicentre study. GISU. Interdisciplinary Group for the Study of Ulcer. Dig Liver Dis (2000) 1.03
The impact of antibiotic resistance on the efficacy of three 7-day regimens against Helicobacter pylori. Aliment Pharmacol Ther (2000) 1.02
Mutations of the Helicobacter pylori genes rdxA and pbp1 cause resistance against metronidazole and amoxicillin. Antimicrob Agents Chemother (2001) 1.02
A change in PBP1 is involved in amoxicillin resistance of clinical isolates of Helicobacter pylori. J Antimicrob Chemother (2002) 1.01
The effect of antibiotic resistance on the outcome of three 1-week triple therapies against Helicobacter pylori. Aliment Pharmacol Ther (1999) 1.00
Evaluation of short-term low-dose triple therapy for the eradication of Helicobacter pylori by factorial design in a randomized, double-blind, controlled study. Aliment Pharmacol Ther (1998) 0.99
Resistance of Helicobacter pylori isolated in Israel to metronidazole, clarithromycin, tetracycline, amoxicillin and cefixime. J Antimicrob Chemother (2002) 0.98
cagA Status and eradication treatment outcome of anti-Helicobacter pylori triple therapies in patients with nonulcer dyspepsia. J Clin Microbiol (2001) 0.98
High-dose rabeprazole-amoxicillin versus rabeprazole-amoxicillin-metronidazole as second-line treatment after failure of the Japanese standard regimen for Helicobacter pylori infection. Aliment Pharmacol Ther (2003) 0.98
Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin. Aliment Pharmacol Ther (2003) 0.97
The HOMER Study: the effect of increasing the dose of metronidazole when given with omeprazole and amoxicillin to cure Helicobacter pylori infection. Helicobacter (2000) 0.97
Second-line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies. Aliment Pharmacol Ther (2003) 0.96
Clarithromycin resistance and eradication of Helicobacter pylori in children. Antimicrob Agents Chemother (2001) 0.96